


796 **Supplemental material**

797

Supplemental Figure 1.



798

799

800 **Supplemental Figure 1. Pre-existing atopy alters mechanistic pathway. SeV**

801 infected atopic mice (H/H/S) demonstrated a reduction in (A) CD49d<sup>+</sup> PMN in BAL and

802 (B) high affinity IgE receptor, FcεRI, expression on lung cDC compared to non-atopic

803 mice (H/P/S). (C) *Ccl28* was also reduced in atopic mouse lungs at day 21 PI SeV


804 (qRT-PCR analysis of *Ccl28* expression normalized to *Gapdh* measured as 2<sup>-ΔΔCT</sup> of

805 mRNA expression). n≥3 mice per group/time point; \*p<0.05, \*\*p<0.01, atopic versus

806 non-atopic

807

Supplemental Figure 2.



808


809

810 **Supplemental Figure 2. Post-viral airway disease is prevented in atopic MPO**  
 811 **deficient mice.**

812 Mice (*Mpo*<sup>-/-</sup>) sensitized and challenged with HDM and infected with SeV (H/H/S) fail to  
 813 develop (A) post-viral AHR (B) MCM, 21d PI SeV or UV-SeV (control). Note that  
 814 infected non-atopic *Mpo*<sup>-/-</sup> mice (P/P/S) did develop increased AHR and MCM. For  
 815 MCM, wild type C57BL6 mice (B6) are included for comparison. n=4 mice per group,  
 816 \*p<0.05, \*\*\*\*p<0.0001 from baseline of each group.

817

Supplemental Figure 3.



818

819 **Supplemental Figure 3. Depletion of lung PMN with anti-Ly6G mAb.** Cells  
820 harvested from lungs after 24h of treatment with isotype control or anti-Ly6G mAb.  
821 Representative dot plots of flow cytometry showing frequency of PMN in mouse lung  
822 24h after isotype control (left) or anti-Ly6G mAb (right) given i.p.